Is DarioHealth Corp. overvalued or undervalued?

As of 11 May 2016, the valuation grade for DarioHealth Corp. changed from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its significant losses and negative valuation metrics. Key ratios include a Price to Book Value of 0.42, an EV to EBIT of -0.67, and an EV to EBITDA of -0.80, all of which reflect a concerning financial position.
In comparison to peers, DarioHealth Corp. has a less favorable EV to EBITDA ratio than Clearpoint Neuro, Inc. (-14.42) and Stereotaxis, Inc. (-11.42), both of which are also classified as risky but show less severe negative metrics. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -60.76% compared to the index's 12.22%, reinforcing the notion that the stock is overvalued.